Skip to content
Open access

LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

Findings support moving beyond LDL-centric assessment toward particle-based phenotyping and provide a mechanistic rationale for early Lp(a)-targeted and anti-inflammatory therapeutic strategies.

Abstract

Early aggressive LDL-C lowering after acute coronary syndrome (ACS) is recommended to reduce recurrent events. Upfront triple oral lipid-lowering therapy is increasingly used to rapidly achieve LDL-C <55 mg/dL. Whether achieving an LDL-C target translates into early normalization of biological risk remains uncertain. To characterize ApoB–corrected LDL discordance and multidomain residual atherogenic and inflammatory risk one month after ACS treated with PCI and universal high-intensity rosuvastatin–ezetimibe–bempedoic acid therapy. In a prospective single-centre cohort of 426 consecutive ACS patients undergoing PCI, all received triple oral lipid-lowering therapy from index hospitalization. At 1 month, corrected LDL-C, ApoB, triglycerides, remnant cholesterol, Lp(a), and hsCRP were assessed. ApoB–LDL discordance was defined using a 2×2 framework (corrected LDL <55 vs ≥55 mg/dL; ApoB ≤65 vs >65 mg/dL). Residual risk domains included LDL non-response, non-HDL-C ≥85 mg/dL, ApoB ≥65 mg/dL, triglycerides ≥150 mg/dL, remnant cholesterol ≥30 mg/dL, Lp(a) >50 mg/dL, and hsCRP ≥2 mg/L. A residual risk burden index was constructed (0, 1, 2, ≥3 domains). Corrected LDL-C <55 mg/dL was achieved in 350 patients (82%). However, among LDL achievers, 86 patients (23.8%) demonstrated ApoB >65 mg/dL despite target LDL-C. This discordant group exhibited higher triglycerides (149 vs 121 mg/dL), higher remnant cholesterol (21 vs 16 mg/dL), and a higher median hsCRP (0.72 vs 0.48 mg/L) than concordant-low patients. Strikingly, Lp(a) >50 mg/dL was present in 94.2% of discordant patients versus 50.8% of concordant-low individuals. Across the entire cohort, complete residual risk normalization was uncommon. Only 19% of patients had zero risk domains at 1 month, whereas 52% exhibited ≥2 domains and 33% had ≥3 domains, indicating substantial clustering of atherogenic and inflammatory risk despite maximal oral therapy. In 426 ACS patients treated with upfront triple oral lipid therapy, achieving LDL-C targets did not equate to biological risk resolution. Nearly one-quarter of LDL achievers demonstrated ApoB discordance with marked enrichment of elevated Lp(a), remnant lipoproteins, and inflammatory activity. Residual risk was multidimensional and frequently clustered early after ACS. These findings support moving beyond LDL-centric assessment toward particle-based phenotyping and provide a mechanistic rationale for early Lp(a)-targeted and anti-inflammatory therapeutic strategies.Figure 1Figure 2

Read PDF

Similar papers

Open access Oct 2026

Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)

Despite strong recommendations from the European Society of Cardiology / European Atherosclerosis Society for low-density lipoprotein cholesterol (LDL-C) <55 mg/dL after acute coronary syndrome (ACS), real-world attainment remains suboptimal. Whether systematic early reassessment, combined with the predominant us...

K. Mahajan, J. B. Sharma, S. Himral et al. · 0 citations
Open access Oct 2026

Early intensive combination lipid-lowering therapy in statin-naïve acute coronary syndrome: real-world attainment of lipid targets and analysis of therapeutic gaps

Inpatient initiation of high-intensity statin plus ezetimibe enabled over 80% of statin-naïve ACS patients to achieve stringent ESC/EAS LDL-C targets with an acceptable safety profile.

Y. Zhang, B. Yan, K. Kam et al. · 0 citations
Open access Oct 2026

Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study

Low LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.

A. Gautam, Sudesh Prajapathi, Abhishek Singh et al. · 0 citations
Open access Sep 2026

LDL-C Target Attainment and Treatment Gaps Six Months After Acute Coronary Syndrome: insights from the CALLINICUS-Hellas registry.

BACKGROUND Low-density lipoprotein cholesterol (LDL-C) reduction is the cornerstone of secondary prevention after acute coronary syndrome (ACS). Despite potent lipid-lowering therapies (LLTs), a therapeutic gap persists. We aimed to evaluate LDL-C target attainment according to the 2019 ESC/EAS guidelines, identify pre...

L. Rallidis, D. Tsamoulis, Despoina-Rafailia Benetou et al. · 0 citations
Review Open access Oct 2026

Upfront combination lipid-lowering therapy in acute coronary syndrome: a bayesian network meta-analysis of low-density lipoprotein cholesterol reduction and major adverse cardiovascular events

Acute coronary syndrome (ACS) is a leading cause of death worldwide. Guidelines recommend initiation of high-intensity statin therapy after ACS, followed by combination therapy in patients who are unable to achieve target low-density lipoprotein cholesterol (LDL-C) lowering. Upfront combination lipid-lowering the...

A. Kulkarni, P. Keerthi, H. M. Bharathkumar et al. · 0 citations
Open access Oct 2026

Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis

Baseline LDL-C category analysis revealed that patients with baseline LDL-C ≥160 mg/dL required triple therapy to reach guideline targets, while those with baseline LDL-C <100 mg/dL achieved targets with high-intensity statin monotherapy.

N. Tsiamis, A. Romiou, D. Zacharakis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.